| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/22/2004 | WO2004032716A2 Compounds for modulation of cholesterol transport |
| 04/22/2004 | WO2004032708A2 Vasoregulating compounds and methods of their use |
| 04/22/2004 | WO2004022657A8 Increasing of the resorption of substances via skin and mucous membranes |
| 04/22/2004 | WO2004020639A3 Production of multimeric fusion proteins using a c4bp scaffold |
| 04/22/2004 | WO2004019965A3 Thymus-based tolerogenic approaches for type i diabetes. |
| 04/22/2004 | WO2004019758A3 Methods of treating idiopathic pulmonary fibrosis |
| 04/22/2004 | WO2004017987A3 Heterocarpin, a plant-derived protein with anti-cancer properties |
| 04/22/2004 | WO2004014852A3 Iminothiazolidinones as inhibitors of hcv replication |
| 04/22/2004 | WO2004007720A3 Treatment of proliferative disorders |
| 04/22/2004 | WO2004007557A3 Tf antagonist |
| 04/22/2004 | WO2004003201A3 Antisense modulation of lrh1 expression |
| 04/22/2004 | WO2004001013A3 Inhibition of gene expression in vertebrates using double-stranded rna (rnai) |
| 04/22/2004 | WO2003105907A3 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases |
| 04/22/2004 | WO2003103770A3 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
| 04/22/2004 | WO2003088812A3 Nor-1 and nur77 nuclear receptors as targets for anti-leukemia therapy |
| 04/22/2004 | WO2003087318A9 Truncated 24 kda basic fibroblast growth factor |
| 04/22/2004 | WO2003086286A3 Treatment of type 1 diabetes before and after expression of predisposition markers |
| 04/22/2004 | WO2003084476A3 Treatment of lung disorder |
| 04/22/2004 | WO2003057722A3 Cyclic tetrapeptide compound and use thereof |
| 04/22/2004 | WO2003051272A9 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GnRH-I AND GnRH-II MODULATION OF T-CELL ACTIVITY, ADHESION, MIGRATION AND EXTRAVASATION |
| 04/22/2004 | WO2003040345A3 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/22/2004 | WO2003040176A3 Peptide decoys for the preparation of medicaments that are intended for the prevention or treatment of autoimmune pathologies or problems linked to the appearance of antibodies directed against exogenous proteins |
| 04/22/2004 | WO2003039346A8 Diagnostics and therapeutics for ocular abnormalities |
| 04/22/2004 | WO2003033738A3 Polymorphic marker that can be used to assess the efficacy of interferon therapy |
| 04/22/2004 | WO2003029428A8 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 04/22/2004 | WO2003029279A9 Immunodominant acetylcholine receptor alpha subunit peptide: mhc complexes |
| 04/22/2004 | WO2003022202A9 Compositions and methods for treatment of cancer |
| 04/22/2004 | WO2003020763A9 Soluble t cell receptor |
| 04/22/2004 | WO2003015809A9 Antimicrobial cationic peptides and formulations thereof |
| 04/22/2004 | WO2003012103A3 Nucleic acids coding for novel fbox proteins, their diagnostic and therapeutic uses |
| 04/22/2004 | WO2002102846A3 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state |
| 04/22/2004 | WO2002100390A3 Improved method of treating the syndrome of coronary heart disease risk factors in humans |
| 04/22/2004 | WO2002100148A3 Treatment or prophylaxis of insulin-producing cell graft rejection |
| 04/22/2004 | WO2002098362A3 Use of rank antagonists to treat cancer |
| 04/22/2004 | WO2002094852A8 Taci-immunoglobulin fusion proteins |
| 04/22/2004 | WO2002092784A3 POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47 |
| 04/22/2004 | WO2002092782A3 Diagnosis and treatment of malignant neoplasms |
| 04/22/2004 | WO2002090567A3 Sperm-specific cation channel, and uses therefor |
| 04/22/2004 | WO2002064731A9 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 04/22/2004 | WO2002059268A9 Factor ixa: factor viiia interaction and methods therefor |
| 04/22/2004 | WO2002058624A9 In situ generation allicin for the treatment of cancer and infectious diseases |
| 04/22/2004 | WO2002022803A9 Peptide epitopes recognized by antigen specific cd4+ t lymphocytes |
| 04/22/2004 | WO2001082949A9 Method of reducing side effects of chemotherapy in cancer patients |
| 04/22/2004 | WO1991007986A8 Method of treating septic shock |
| 04/22/2004 | WO1990013281A3 Method of suppressing hiv infection |
| 04/22/2004 | US20040078842 Protein with endo-chitinase activity |
| 04/22/2004 | US20040078837 Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12 |
| 04/22/2004 | US20040078836 Diacylglycerol O-Acyltransferase |
| 04/22/2004 | US20040077879 Building blocks linked together through the formation of rigid diketopiperazine rings |
| 04/22/2004 | US20040077847 Nucleic acid encoding a pneumoccocal surface protein c gene or epitope |
| 04/22/2004 | US20040077843 Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
| 04/22/2004 | US20040077837 Microtubule-associated proteins and tubulins |
| 04/22/2004 | US20040077835 For treatment of disorders involving the naturally occurring chemokine such as HIV and AIDS related disorders, asthma, allergic rhinitis, atopic dermatitis, atherosclerosis, organ transplant rejection, and rheumatoid arthritis |
| 04/22/2004 | US20040077834 Determining whether a mammal has a disorder associated with the presence of drug-resistant cells having increased DRT111 expression (e.g. drug-resistant cancer), and administering to the mammal a compound that reduces the expression of DRT111 |
| 04/22/2004 | US20040077833 Regulation of human mrp5-like protein |
| 04/22/2004 | US20040077832 Jfy1protein induces rapid apoptosis |
| 04/22/2004 | US20040077828 Proteins containing the motif that are capable of binding to secreted Frizzled-related protein (Sfrp) family members |
| 04/22/2004 | US20040077780 Thermogelling oligopeptide polymers |
| 04/22/2004 | US20040077620 Hypoglycemic agent |
| 04/22/2004 | US20040077611 Triple therapy of angiotensin converting enzyme inhibitor epoxy-steroidal aldosterone antagonist and diuretic or digoxin for treatment of cardiovascular disease |
| 04/22/2004 | US20040077601 Methods and compositions relating to isoleucine boroproline compounds |
| 04/22/2004 | US20040077587 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 04/22/2004 | US20040077583 Antisense modulation of BCL2-associated X protein expression |
| 04/22/2004 | US20040077580 Phosphatidylinositol 3-kinase (PI3K) inhibitors; hyperpro-liferative disorders, metabolic disease, diabetes, type 2 diabetes, obesity |
| 04/22/2004 | US20040077578 Inhibition; hybridizing mRNA target; cancer |
| 04/22/2004 | US20040077574 Protein tyrosine phosphatase inhibitors |
| 04/22/2004 | US20040077573 Suppresses overexpression; reducing side effects; such as preventing occurance of plethora while treating anemia with erythropoietin |
| 04/22/2004 | US20040077571 Such as oligonucleotides with phosphorothioate backbones |
| 04/22/2004 | US20040077566 Methods and compositions for the treatment and diagnosis of body weight disorders |
| 04/22/2004 | US20040077565 Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| 04/22/2004 | US20040077553 Such as 1-(((alpha-propanoyloxybutoxy)carbonyl)aminomethyl)-1-cyclohexane acetic acid; ability to cross blood brain barrier; sustained release |
| 04/22/2004 | US20040077552 Inflammation-inhibiting compounds |
| 04/22/2004 | US20040077551 NS3 protease inhibitors; quinoline derivatives |
| 04/22/2004 | US20040077549 Inhibitors of the E2F-1/cyclin interaction for cancer therapy |
| 04/22/2004 | US20040077547 Preventing catalytic conversion of factors X, VII AND IX to Xa, VIIa and IXa respectively |
| 04/22/2004 | US20040077546 Osteogenic proteins |
| 04/22/2004 | US20040077545 Synthetic peptide for neurological disorders |
| 04/22/2004 | US20040077544 Specific interference with alpha 5 beta 1 integrin and fibronectin binding |
| 04/22/2004 | US20040077543 Treatment using neublastin polypeptides |
| 04/22/2004 | US20040077541 Methods of using non-human animal Apolipoprotein A-I protein |
| 04/22/2004 | US20040077540 Permeabilizing peptide; reversibly enhancing paracellular transport; inhibits homotypic binding |
| 04/22/2004 | US20040077539 Stimulating growth of lactic acid producing bacteria in gastrointestinal tract; enriched whey protein concentrate |
| 04/22/2004 | US20040077538 Activates patients own factor VII to VIIa; limits thrombin formation |
| 04/22/2004 | US20040077537 Method for treating congestive heart failure |
| 04/22/2004 | US20040077536 Human and rat pgc-3, ppar-gamma coactivations and splice variants thereof |
| 04/22/2004 | US20040077535 Novel physiologically active peptide and use thereof |
| 04/22/2004 | US20040077534 Methods and compositions for the treatment and prevention of Staphylococcus a ureus infections |
| 04/22/2004 | US20040077532 Aglyco products and methods of use |
| 04/22/2004 | US20040077531 Regulating luteotropic hormone secretion; amino acid sequence 35 |
| 04/22/2004 | US20040077530 Stimulating release of cholecystokinin following ingestion; glycomacropeptides alone; efficiency |
| 04/22/2004 | US20040077528 Entrapping active agent in fumaryl diketopiperazine derivative and solvent washing out impurities; purified insulin for pulmonary administration |
| 04/22/2004 | US20040077526 SR-BI antagonist and use thereof as contraceptives and in the treatment of steroidal overproduction |
| 04/22/2004 | US20040077085 Antisense modulation of CDC14A expression |
| 04/22/2004 | US20040077084 Antisense modulation of histone deacetylase 4 expression |
| 04/22/2004 | US20040077083 For treatment of diseases associated with expression of Histone deacetylase 4 such as leukemia |
| 04/22/2004 | US20040077082 Oligonucleotides with 5'- and 3'-terminal hairpins that may be configured to regulate the expression of a gene |
| 04/22/2004 | US20040077064 Identification and isolation of novel DNA and to the recombinant production of novel polypeptides |
| 04/22/2004 | US20040077054 N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin; used in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormal placental |
| 04/22/2004 | US20040077051 LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications |
| 04/22/2004 | US20040077049 For preventing, ameliorating, disorders or diseases including cancer, peripheral and central nervous system disorders, genitourinary disorders, cardiovascular disorders, and Chronic obstructive pulmonary (or airways) disease (COPD) |